Push­ing ahead with can­cer drug re­search, Pelo­ton brings its lat­est round to $75M

Dal­las-based Pelo­ton Ther­a­peu­tics has bagged an ex­tra $22.2 mil­lion for its Se­ries D round, bring­ing the to­tal to $74.6 mil­lion.

Much of that mon­ey is be­ing ear­marked for PT2385, an ear­ly-stage drug which Pelo­ton sees as a “first-in-class” small mol­e­cule tar­get­ing hy­pox­ia in­ducible fac­tor-2α (HIF-2α), a tran­scrip­tion fac­tor in­volved in can­cer pro­gres­sion. Their lead pro­gram is cur­rent­ly in a Phase I study for clear cell re­nal cell car­ci­no­ma, or ccR­CC.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.